Key Findings to Watch in SENTRY Trial of Selinexor/Ruxolitinib in Myelofibrosis

Prithviraj Bose, MD, and Pankit Vachhani, MD, discuss the primary objectives and clinically meaningful end points of the phase 3 SENTRY trial (NCT04562389). Bose highlights key efficacy measures such as spleen response, symptom improvement, and durability of benefit that will determine the regimen’s clinical impact. Vachhani also notes the importance of safety and tolerability data in assessing the feasibility of incorporating combination therapy with selinexor (Xpovio) plus ruxolitinib (Jakafi) into routine practice.